Pharmabiz1d
Intellia Therapeutics doses first patient in MAGNITUDE-2 phase 3 study of nexiguran ziclumeran
Intellia Therapeutics doses first patient in MAGNITUDE-2 phase 3 study of nexiguran ziclumeran: Cambridge, Massachusetts Saturday, April 5, 2025, 18:00 Hrs [IST] Intellia Therapeu ...
Pharmabiz1d
Vera Therapeutics completes full enrollment in pivotal ORIGIN phase 3 trial for Atacicept in patients with IgA nephropathy
Brisbane, California Saturday, April 5, 2025, 15:00 Hrs [IST] ...
Pharmabiz2d
Kapadia Hospital joins India’s first AI surgery revolution with MISSO, hailed by PM Modi
Kapadia Hospital joins India’s first AI surgery revolution with MISSO, hailed by PM Modi: Our Bureau, Mumbai Friday, April 4, ...
Pharmabiz1d
Pacira BioSciences begins patient dosing in phase 2 study evaluating safety and efficacy of PCRX-201 to treat osteoarthritis of the knee
Pacira BioSciences begins patient dosing in phase 2 study evaluating safety and efficacy of PCRX-201 to treat osteoarthritis of the knee: Brisbane, California Saturday, April 5, 2 ...
Pharmabiz1d
EU approves AstraZeneca’s Imfinzi-in combo with chemotherapy to treat patients with resectable non-small cell lung cancer
EU approves AstraZeneca’s Imfinzi-in combo with chemotherapy to treat patients with resectable non-small cell lung cancer ...
Pharmabiz1d
US FDA approves Amgen’s Uplizna to treat IgG4-related disease
US FDA approves Amgen’s Uplizna to treat IgG4-related disease: Thousand Oaks, California Saturday, April 5, 2025, 11:00 Hrs [IST] Amgen announced that the US Food and Drug Admin ...
Pharmabiz1d
Reciprocal tariff may pose significant challenge to growth of medical devices sector: AiMeD
Reciprocal tariff may pose significant challenge to growth of medical devices sector: AiMeD: Our Bureau, New Delhi Saturday, ...
Pharmabiz2d
Boehringer Ingelheim strengthens antibody-drug conjugate portfolio with new NBE Therapeutics R&D centre in Basel
Basel, Switzerland Friday, April 4, 2025, 10:00 Hrs [IST] ...
Pharmabiz1d
Clinical Trials Information System designated as WHO primary registry
The Clinical Trials Information System (CTIS) has been designated as a primary registry by the World Health Organisation (WHO) within the International Clinical Trials Registry Platform (ICTRP).
Pharmabiz1d
Indian healthcare sees urgent need for skill development to offset shortfall of doctors, nurses and paramedics
Nandita Vijayasimha, Bengaluru Saturday, April 5, 2025, 08:00 Hrs [IST] ...
Pharmabiz2d
Abbott introduces next-generation delivery system to streamline electrode placement during dorsal root ganglion stimulator implantations
Abbott Park, Illinois Friday, April 4, 2025, 15:00 Hrs [IST] ...
Pharmabiz2d
Biologit boosts patient safety with automated local literature monitoring solution for non-indexed sources
Biologit boosts patient safety with automated local literature monitoring solution for non-indexed sources: Dublin, Ireland Friday, April 4, 2025, 18:00 Hrs [IST] Biologit, a spec ...